Akili

Akili is in the process of building clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. Their aim is to develop a new type of Digital Medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians. Akili functions on the premise that advances in neuroscience research and consumer-facing technology are enabling a new way to sensitively measure neural function, and intervene in any measured deficits, wherever the patient may be. Akili's products address both quantitative measurement of and intensive intervention in cognitive functions in a variety of patient populations. Akili was co-founded by PureTech, leading cognitive neuroscientists, and top-tier entertainment software creators.

http://www.akiliinteractive.com/

Team Members
more about
Edward Kliphuis
more about
Caroline Rufo
more about
Tiziana Rossetti
Latest News Entry
2016/07/20
Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million

BOSTON--(BUSINESS WIRE)-- Akili Interactive Labs, Inc. ("Akili"), a digital medicine company developing novel, non-pharmacological therapeutics and diagnostics for cognitive disorders, today announced an $11.9 million expansion of its recent Series B financing. *Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States and Canada), and Amgen Ventures, the venture arm of Amgen, joined existing investors to bring the total Series B proceeds to $42.4 million. Akili will use the funds to support and expand clinical development of its clinical-stage products into new areas, with an expanded focus on neurodegeneration, and to build out its commercial infrastructure as Akili nears the market with its late-stage products. With the M Ventures and Amgen Ventures investments, Akili now has four relationships with major biopharma companies or their investment affiliates, including its existing partnership with Pfizer, Inc. and an investment from Shire Pharmaceuticals.

all portfolio news